GCG and type 2 diabetes mellitus: Third, sodium/glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) analogues have renoprotective actions in patients with type 2 diabetes beyond glycemic control.